Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04611789 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3832479 (LY-CoV016) in Healthy Participants 1
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT04611789 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 18 participants.
The verdict
NCT04611789, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and tolerability of LY3832479 when it is given by injection just under the skin to healthy participants. Blood tests will be done to check how much LY3832479 is in the bloodstream and how long the body takes to eliminate it. Participation could last up to 16 weeks and may include up to six visits to the study center, with a one-week overnight stay.
Interventions
- DRUG Placebo
- DRUG LY3832479
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-11-02 |
| Est. Completion | 2021-02-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04611789
The ClinicalTrials.gov registry entry for NCT04611789 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04611789 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04611789 about?
NCT04611789 is a clinical study titled "A Study of LY3832479 (LY-CoV016) in Healthy Participants 1". The purpose of this study is to test the safety and tolerability of LY3832479 when it is given by injection just under the skin to healthy participants. Blood tests will be done to check how much LY3832479 is in the bloodstream and how long the body takes to eliminate it. Participation could last up...
What is the current status of trial NCT04611789?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2020-11-02. Estimated completion is 2021-02-10.
What interventions are being tested in trial NCT04611789?
The interventions under investigation include: Placebo (DRUG), LY3832479 (DRUG).
Who is sponsoring clinical trial NCT04611789?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.